These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 26332198)

  • 1. NOS1AP Polymorphisms Modify QTc Interval Duration But Not Cardiac Arrest Risk in Hypertrophic Cardiomyopathy.
    Earle N; Ingles J; Bagnall RD; Gray B; Crawford J; Smith W; Shelling AN; Love DR; Semsarian C; Skinner JR
    J Cardiovasc Electrophysiol; 2015 Dec; 26(12):1346-51. PubMed ID: 26332198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single nucleotide polymorphisms in arrhythmia genes modify the risk of cardiac events and sudden death in long QT syndrome.
    Earle N; Yeo Han D; Pilbrow A; Crawford J; Smith W; Shelling AN; Cameron V; Love DR; Skinner JR
    Heart Rhythm; 2014 Jan; 11(1):76-82. PubMed ID: 24096169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. QT prolongation and sudden cardiac death risk in hypertrophic cardiomyopathy.
    Patel SI; Ackerman MJ; Shamoun FE; Geske JB; Ommen SR; Love WT; Cha SS; Bos JM; Lester SJ
    Acta Cardiol; 2019 Feb; 74(1):53-58. PubMed ID: 29513133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. QRS Fragmentation and QTc Duration Relate to Malignant Ventricular Tachyarrhythmias and Sudden Cardiac Death in Patients with Hypertrophic Cardiomyopathy.
    Debonnaire P; Katsanos S; Joyce E; VAN DEN Brink OV; Atsma DE; Schalij MJ; Bax JJ; Delgado V; Marsan NA
    J Cardiovasc Electrophysiol; 2015 May; 26(5):547-55. PubMed ID: 25648421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Common NOS1AP variants are associated with a prolonged QTc interval in the Rotterdam Study.
    Aarnoudse AJ; Newton-Cheh C; de Bakker PI; Straus SM; Kors JA; Hofman A; Uitterlinden AG; Witteman JC; Stricker BH
    Circulation; 2007 Jul; 116(1):10-6. PubMed ID: 17576865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolongation of the QTc interval predicts appropriate implantable cardioverter-defibrillator therapies in hypertrophic cardiomyopathy.
    Gray B; Ingles J; Medi C; Semsarian C
    JACC Heart Fail; 2013 Apr; 1(2):149-55. PubMed ID: 24621839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis for Genetic Modifiers of Disease Severity in Patients With Long-QT Syndrome Type 2.
    Kolder ICRM; Tanck MWT; Postema PG; Barc J; Sinner MF; Zumhagen S; Husemann A; Stallmeyer B; Koopmann TT; Hofman N; Pfeufer A; Lichtner P; Meitinger T; Beckmann BM; Myerburg RJ; Bishopric NH; Roden DM; Kääb S; Wilde AAM; Schott JJ; Schulze-Bahr E; Bezzina CR
    Circ Cardiovasc Genet; 2015 Jun; 8(3):447-456. PubMed ID: 25737393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy.
    Elliott PM; Sharma S; Varnava A; Poloniecki J; Rowland E; McKenna WJ
    J Am Coll Cardiol; 1999 May; 33(6):1596-601. PubMed ID: 10334430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating Common NOS1AP Variants in Patients with Implantable Cardioverter Defibrillators for Secondary Prevention : Evaluating SNPs in NOS1AP.
    Zang X; Zhang S; Li S; Wang X; Song W; Chen K; Ma J; Tu X; Xia Y; Zhao Y; Gao C
    J Interv Card Electrophysiol; 2022 Sep; 64(3):793-800. PubMed ID: 35353321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A common variant of NOS1AP is associated with QT interval duration in a Chinese population with Type 2 diabetes.
    Lu J; Hu C; Hu W; Zhang R; Wang C; Qin W; Yu W; Xiang K; ; Jia W
    Diabet Med; 2010 Sep; 27(9):1074-9. PubMed ID: 20722683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms in the NOS1AP gene modulate QT interval duration and risk of arrhythmias in the long QT syndrome.
    Tomás M; Napolitano C; De Giuli L; Bloise R; Subirana I; Malovini A; Bellazzi R; Arking DE; Marban E; Chakravarti A; Spooner PM; Priori SG
    J Am Coll Cardiol; 2010 Jun; 55(24):2745-52. PubMed ID: 20538168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the new risk prediction model (HCM Risk-SCD) and classic risk factors for sudden death in patients with hypertrophic cardiomyopathy and defibrillator.
    Ruiz-Salas A; García-Pinilla JM; Cabrera-Bueno F; Fernández-Pastor J; Peña-Hernández J; Medina-Palomo C; Barrera-Cordero A; De Teresa E; Alzueta J
    Europace; 2016 May; 18(5):773-7. PubMed ID: 25855675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A common NOS1AP genetic polymorphism, rs12567209 G>A, is associated with sudden cardiac death in patients with chronic heart failure in the Chinese Han population.
    Liu X; Pei J; Hou C; Liu N; Chu J; Pu J; Zhang S
    J Card Fail; 2014 Apr; 20(4):244-51. PubMed ID: 24418727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients.
    Alsheikh-Ali AA; Link MS; Semsarian C; Shen WK; Estes NA; Maron MS; Haas TS; Formisano F; Boriani G; Spirito P; Maron BJ
    Heart Rhythm; 2013 Feb; 10(2):214-8. PubMed ID: 23041573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of QTc Interval and V4-S Wave With Appropriate ICD Therapy in Hypertrophic Cardiomyopathy.
    Zhang N; Cheng S; Niu H; Gu M; Peng H; Sun Z; Liu X; Deng Y; Chen X; Hua W
    Front Cardiovasc Med; 2022; 9():882662. PubMed ID: 35647065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between myocardial fibrosis detected by cardiac magnetic resonance and Tp-e interval, 5-year sudden cardiac death risk score in hypertrophic cardiomyopathy patients.
    Riza Demir A; Celik Ö; Sevinç S; Uygur B; Kahraman S; Yilmaz E; Cemek M; Onal Y; Erturk M
    Ann Noninvasive Electrocardiol; 2019 Sep; 24(5):e12672. PubMed ID: 31152489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
    Noseworthy PA; Rosenberg MA; Fifer MA; Palacios IF; Lowry PA; Ruskin JN; Sanborn DM; Picard MH; Vlahakes GJ; Mela T; Das S
    Am J Cardiol; 2009 Jul; 104(1):128-32. PubMed ID: 19576333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcium channel blockers, NOS1AP, and heart-rate-corrected QT prolongation.
    van Noord C; Aarnoudse AJ; Eijgelsheim M; Sturkenboom MC; Straus SM; Hofman A; Kors JA; Newton-Cheh C; Witteman JC; Stricker BH
    Pharmacogenet Genomics; 2009 Apr; 19(4):260-6. PubMed ID: 19247217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic variations in nitric oxide synthase 1 adaptor protein are associated with sudden cardiac death in US white community-based populations.
    Kao WH; Arking DE; Post W; Rea TD; Sotoodehnia N; Prineas RJ; Bishe B; Doan BQ; Boerwinkle E; Psaty BM; Tomaselli GF; Coresh J; Siscovick DS; Marbán E; Spooner PM; Burke GL; Chakravarti A
    Circulation; 2009 Feb; 119(7):940-51. PubMed ID: 19204306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of NOS1AP Risk Variants on the Corrected QT (QTc) Interval in the Pharmacotherapy of Schizophrenia.
    Esen-Sehir D; Kopf J; Hägele S; Plichta MM; Reif A; Freudenberg F
    Pharmacopsychiatry; 2022 Sep; 55(5):266-273. PubMed ID: 35732169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.